Physician profile
Nancy Chen
NPI 1265427900
$6,220.91
in general payments reported to CMS, 2019-2025
27 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $369 · 2021: $554 · 2022: $324 · 2023: $1,084 · 2024: $554 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.59 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,827.55 | 2019-2025 | Unity, Argos, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $546.44 | 2019-2021 | |
| Amgen INC. | $503.39 | 2024-2025 | Tepezza |
| Glaukos Corporation | $450.92 | 2024-2025 | Idosetr, Istent Infinite, Idose |
| New World Medical,INC. | $438.26 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $408.47 | 2019 | |
| Sight Sciences, INC. | $302.65 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $208.90 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $184.93 | 2019 | |
| Merz North America, INC. | $161.18 | 2019-2020 | |
| Horizon Therapeutics Plc | $155.61 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $144.48 | 2019-2023 | Cequa, Xelpros |
| Kedrion Biopharma, INC. | $124.96 | 2025 | Coagadex |
| Genentech USA, INC. | $123.56 | 2019 | |
| Dompe US, INC. | $120.00 | 2023 | Oxervate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $86.21 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $82.80 | 2023-2025 | Vyzulta, Prolensa, Miebo |
| Novartis Pharmaceuticals Corporation | $70.44 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $56.31 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $52.74 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $36.16 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $29.24 | 2025 | Purified Cortrophin Gel |
| Galderma Laboratories, L.P. | $27.20 | 2019 | |
| Harrow Eye, LLC | $25.20 | 2025 | Vevye |
| Shire North American Group INC | $19.96 | 2019 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.